Cargando…
Valemetostat Tosilate: First Approval
Valemetostat tosilate (valemetostat; EZHARMIA(®)), a selective dual inhibitor of histone-lysine N-methyltransferases enhancer of zeste homolog 1 and 2 (EZH1/2), is being developed by Daiichi Sankyo Company, Ltd for the treatment of various haematological malignancies and solid tumours, including typ...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9705507/ https://www.ncbi.nlm.nih.gov/pubmed/36380144 http://dx.doi.org/10.1007/s40265-022-01800-5 |